Detalhe da pesquisa
1.
"That was a tip from my physician"-Gender-specific pathways of patients and relatives to outpatient psychosocial cancer counselling centres-A qualitative study.
Psychooncology
; 31(6): 1022-1030, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35103358
2.
Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors.
J Oncol Pharm Pract
; 27(5): 1147-1158, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32746691
3.
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.
Front Oncol
; 14: 1283266, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38384801
4.
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Eur J Cancer
; 201: 113911, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38377774
5.
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer.
Front Oncol
; 13: 1273478, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37810988
6.
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis.
Ther Adv Med Oncol
; 14: 17588359221097191, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35677321
7.
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP.
Data Brief
; 34: 106556, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33364266
8.
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Ther Adv Med Oncol
; 13: 1758835920980558, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33613692
9.
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Lung Cancer
; 154: 51-61, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33611226
10.
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
J Thorac Oncol
; 16(11): 1952-1958, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34245914
11.
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Lung Cancer
; 150: 114-122, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33126091
12.
Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Oncol Res Treat
; 42(5): 243-255, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30995666
13.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
J Immunother Cancer
; 7(1): 38, 2019 02 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30736848
14.
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
J Cancer Res Clin Oncol
; 144(12): 2457-2463, 2018 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-30244389
15.
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
J Clin Oncol
; 30(33): 4117-23, 2012 Nov 20.
Artigo
Inglês
| MEDLINE | ID: mdl-23045592